Moving from Vial to Prefilled Syringe - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Moving from Vial to Prefilled Syringe
A Project Manager's Perspective.


Pharmaceutical Technology


References

1. J.A. DiMasi, R.W. Hansen, and H.G. Grabowski, "The Price of Innovation: New Estimates of Drug Development Costs," Jrnl. of Health Econ. 22 (2), p. 151 (2003).

2. B. Harrison and M. Rios, "Big Shot: Developments in Prefilled Syringes," Pharm. Technol. 31 (3) 50–60 (2007).

3. Frost and Sullivan, US Drug Delivery: Usage Patterns, Preferences and Opportunities in the USPhysicians' Perspective, Vol. 2, 2008.

4. Frost and Sullivan, US Drug Delivery: Usage Patterns, Preferences and Opportunities in the US—The Patient's Perspective, Vol. 1, 2008.

5. M. Borlet, "Financial Model for Converting from a Vial to a Pre-filled Syringe," in The Universe of Pre-Filled Syringes and Injection Devices, presented at PDA, San Diego, CA, 2008.

6. T. Polen, "Enhanced Packaging and Reformulations Give New Life to Biologics," BioPharm Int. 19 (10) 60–66 (2006).

7. FDA, 21 USC 356a, Sec. 506 A, Manufacturing Changes (Bethesda, MD, 2009).

8. R. Gibson, "Moving to a Pre-filled Syringe: Stability Considerations—A Regulatory Perspective" in The Universe of Pre-Filled Syringes and Injection Devices, presented at PDA, San Diego, CA, 2008.

9. Code of Federal Regulations, Title 21, Food and Drugs (Government Printing Office, Washington, DC), Part 211.166.

10. K. Davis, "Biopharmaceutical Manufacturing: The Challenge of Global Regulatory Compliance," Pharm. Technol. 32 (2) 60–68 (2008).

11. Drugs@FDA, http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search.DrugDetails, accessed July 7, 2009.

12. FDA, Approval Letter: Fluzone, Sept. 4, 2002 (updated May 15, 2009), http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm123732.htm, accessed July 8, 2009.

13. FDA, Approval Letter—Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant, June 8, 2006 (updated May 1, 2009), http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm111283.htm, accessed July 8, 2009.

14. FDA, Approval Letter, Feb. 17, 2000 (updated Mar. 4, 2002), http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm137057.htm, accessed July 8, 2009.

15. FDA Approved Products, Pneumococcal 7-valent Conjugate Vaccine [package insert], Oct. 2008, http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM137038.pdf, accessed July 8, 2009.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here